Stay informed of CLS government relations efforts, view priority legislation and use our convenient tools to find and contact your elected officials.

California Life Sciences asks Congress to quickly pass user fee agreements to fund the FDA

Sep 13, 2022

September 13, 2022 Dear California Delegation and Congressional Leadership, On behalf of California Life Sciences (CLS), I am writing to urge timely reauthorization of user fee agreements for fiscal years..

Read More

California Life Sciences releases statement after passage of the Inflation Reduction Act

Aug 12, 2022

August 12, 2022 SOUTH SAN FRANCISCO, LOS ANGELES, SAN DIEGO, WASHINGTON D.C. — California Life Sciences (CLS), the state’s most influential life sciences membership organization,  released the following statement after..

Read More

OPEN LETTER: 31 biopharmaceutical CEOs urge Congress to protect the life sciences industry

Aug 4, 2022

August 4, 2022 California Representatives and Senators U.S. Congress Washington, DC We write as the leadership of small and emerging biopharmaceutical companies in California that represent the leading edge of..

Read More

CLS joins the Council of State Bioscience Associations to express concerns about drug pricing proposals

Jul 20, 2022

July 20, 2022 Dear Senate Majority Leader Schumer, Senate Republican Leader McConnell, House Speaker Pelosi, and House Republican Leader McCarthy: The Council of State Bioscience Associations (CSBA) is an alliance..

Read More

CLS PROVIDES WHITE HOUSE INFORMATION ON STRENGTHENING COMMUNITY HEALTH THROUGH TECHNOLOGY

Mar 31, 2022

March 31st, 2022 SUBMITTED ELECTRONICALLY Jacqueline Ward, White House Office of Science and Technology Policy (OSTP) RE: Request for Information on Strengthening Community Health Through Technology On behalf of the..

Read More

California Life Sciences sends letter to Department of Commerce on behalf of medical device companies

Jan 17, 2022

November 22nd, 2021 RE: Semiconductor chip shortage impact on Medical Devices The Honorable Gina Raimondo Department of Commerce Washington, D.C. 20500 The Honorable Brian Deese National Economic Council Washington, D.C...

Read More

CALIFORNIA LIFE SCIENCES ASKS CONGRESS TO SUPPORT ORPHAN DRUG TAX CREDIT

Sep 28, 2021

Washington, DC—California Life Sciences (CLS) is calling on the California Congressional Delegation to support the Orphan Drug Tax Credit (ODTC). CLS has expressed strong concern with Section 138141 of the..

Read More

Policy Priority: R&D Tax Credit and NOL Deductions

Aug 27, 2021

The restoration of California’s Research and Development (R&D) tax credit and Net Operating Loss (NOL) deduction has been one of California Life Sciences’ (CLS) top priorities for 2021.

Read More

[RECAP] Conversation with Thought Leaders: Health Equity

Jun 30, 2021

Watch the recap of Conversation with Thought Leaders: Health Equity, which explored the importance of increasing health access to underserved communities and how the life sciences community can help tackle..

Read More

Top three issues of SB 605: Medical Device Right to Repair Act

Jun 9, 2021

For the 2021-2022 Legislative Session, Senator Susan Eggman (D-Stockton) introduced SB 605, the Medical Device Right to Repair Act, which would allow health care facilities to contract out repairs for..

Read More

Cal-OSHA Votes on Workplace Rules

Jun 3, 2021

On Thursday, June 3, Cal-OSHA met to discuss workplace rules and COVID-19. After meeting for almost 10 hours, the board ultimately voted to allow workers in a room to take..

Read More

CLS Requests Support For Legislation To Restore R&D Tax Credit To Assist With The State’s Economic Recovery

Mar 26, 2021

The California Life Sciences Association (CLSA) sponsored and introduced Assembly Bill (AB) 593, with Assemblymember Cottie Petrie-Norris (AD 74) which reinstates the Research and Development (R&D) Tax Credit and Net Operating Loss (NOL) deductions for life sciences companies in California for tax years 2021 and 2022.

Read More

New Data Show Foreign Reference Drug Pricing Proposals Would Reduce The Development Of New Innovative Medicines In California By 88%

Mar 24, 2021

Biocom California and the California Life Sciences Association (CLSA) today released data analyzing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.

Read More

CLSA Applauds The Release The Medicare Coverage Of Innovative Technology (MCIT) Final Rule

Jan 28, 2021

Earlier this month, the Centers for Medicare and Medicaid Services (CMS) released the final “Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘Reasonable and Necessary” rule (42 CFR Part 405).  The rule, if implemented as planned in March of this year, creates a pathway for automatic CMS coverage – for 4 years – of medical devices that receive Food and Drug Administration (FDA) breakthrough technologies program designation and subsequent market authorization through their Expedited Review Approval Process.

Read More

California Unveils New Approach To Vaccine Allocation And Distribution

Jan 27, 2021

On Tuesday, January 26, Governor Newsom revised the vaccine rollout plan to help streamline allocation and distribution. Vaccine distribution will now be led by the Government Operations Agency along with CA Health and Human Services and CA Department of Public Health.

Read More

CLSA And BIO Hosted A Briefing “The Transformative Potential Of Gene Therapies”

Jan 27, 2021

On Tuesday, January 26th CLSA and BIO hosted a briefing titled, “The Transformative Potential of Gene Therapies” in partnership with the California Select Committee on Biotechnology and the California Rare Disease Caucus. This briefing was moderated by Assemblymember Kevin Mullin and was attended by legislators, legislative staff and members of the rare disease community who are interested in learning more about gene therapies.

Read More